India, Jan. 6 -- Genprex, Inc. (GNPX) on Tuesday reported preliminary preclinical data showing its diabetes gene therapy candidate GPX-002 improved glucose control in Type 2 diabetes animal models.
In studies involving non-human primates and mice, GPX-002 led to sustained improvements in glucose tolerance and reduced insulin requirements, with one primate achieving normal glucose levels several months after treatment. The company said the results support GPX-002's potential to restore pancreatic cell function.
Genprex is continuing preclinical testing in Type 1 and Type 2 diabetes models and plans to advance GPX-002 toward human clinical trials, including toxicology studies and a future IND submission.
Genprex shares rose more than 5% af...